What is the patisiran SPC (SmPC) used for?
Patisiran is an RNA-targeting medicine used in people with hereditary transthyretin amyloidosis (hATTR amyloidosis) with polyneuropathy. The product information typically described in the SPC/SmPC covers the approved patient population, dosing, method of administration, and safety information (including warnings and monitoring requirements).
What does the patisiran SPC usually include (key sections)?
The SPC/SmPC for patisiran generally contains:
- Indications (who it is for)
- Dosage and method of administration (including infusion details and premedication/monitoring where required)
- Contraindications
- Special warnings and precautions (common safety themes such as infusion-related reactions and monitoring)
- Interactions
- Pregnancy and lactation information
- Adverse reactions
- Pharmacological properties (mechanism and clinical pharmacology)
- Packaging and pharmaceutical particulars
How is patisiran given according to the SPC?
Patisiran is administered by intravenous infusion on a fixed schedule (the SPC specifies the dose per body weight and the infusion interval). The SPC also describes supportive care around the infusion (premedication and monitoring) to reduce the risk of reactions during administration.
What side effects should patients watch for (SPC safety focus)?
SPCs for medicines like patisiran commonly highlight:
- Infusion-related reactions (often the most immediate safety issue around dosing)
- Other adverse events tracked in clinical studies
- When to seek urgent medical care, and what monitoring clinicians should perform
Where can I find the official patisiran SPC text?
For the most up-to-date official product information (SPC/SmPC), you typically need the document published by the relevant regulator for your country (for example, the European Medicines Agency for EU markets, or the national medicines agency for other regions).
If you tell me your country/market (EU, UK, US, etc.) I can point you to the correct official SPC link. If your goal is patent or exclusivity research for patisiran, DrugPatentWatch.com can also help track related intellectual property.
Sources: none provided.